ENANTA PHARMACEUTICALS, INC Additional Paid in Capital, Common Stock
ENANTA PHARMACEUTICALS, INC (ENTA) had Additional Paid in Capital, Common Stock of $551.16 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-12
- 2026-06-30: Additional Paid in Capital, Common Stock $551.16M.
- 2026-03-31: Additional Paid in Capital, Common Stock $546.99M.
- 2025-12-31: Additional Paid in Capital, Common Stock $543.50M.
- 2025-09-30: Additional Paid in Capital, Common Stock $469.77M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $551.16M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $546.99M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $543.50M 10-Q · filed 2026-02-11 |
| 2025-09-30 | $469.77M 10-Q · filed 2026-08-12 |
| 2025-06-30 | $465.70M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $461.52M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $456.96M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $451.34M 10-K · filed 2025-11-19 |
| 2024-06-30 | $443.57M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $438.13M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $432.61M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $424.69M 10-K · filed 2024-11-27 |
| 2023-06-30 | $418.00M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $410.80M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $405.47M 10-Q · filed 2023-02-08 |
| 2022-09-30 | $398.03M 10-K · filed 2023-11-22 |
| 2022-06-30 | $388.27M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $376.55M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $366.72M 10-Q · filed 2022-02-10 |
| 2021-09-30 | $351.03M 10-K · filed 2022-11-23 |
| 2021-06-30 | $344.74M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $338.58M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $332.14M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $326.96M 10-K · filed 2021-11-24 |
| 2020-06-30 | $321.99M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $314.00M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $304.67M 10-Q · filed 2020-02-10 |
| 2019-09-30 | $298.41M 10-K · filed 2020-11-25 |
| 2019-06-30 | $293.19M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $288.51M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $283.53M 10-Q · filed 2019-02-08 |
| 2018-09-30 | $276.53M 10-K · filed 2019-11-27 |
| 2018-06-30 | $271.37M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $264.35M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $260.75M 10-Q · filed 2018-02-09 |
| 2017-09-30 | $256.24M 10-K · filed 2018-11-29 |
| 2017-06-30 | $251.96M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $248.65M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $245.40M 10-Q · filed 2017-02-09 |
| 2016-09-30 | $242.08M 10-K · filed 2017-12-11 |
| 2016-06-30 | $239.25M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $235.50M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $232.11M 10-Q · filed 2016-02-09 |
| 2015-09-30 | $229.96M 10-K · filed 2016-12-09 |
| 2015-06-30 | $228.00M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $226.29M 10-Q · filed 2015-05-08 |
| 2014-09-30 | $221.58M 10-K · filed 2015-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |